Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chronic Severe Plaque-type Psoriasis”

46 trials

Showing 20 of 46 results

Large-scale testing (Phase 3)Study completedNCT02471144
What this trial is testing

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Who this might be right for
Chronic Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 162
Testing effectiveness (Phase 2)Study completedNCT03000075
What this trial is testing

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
AbbVie 182
Large-scale testing (Phase 3)Study completedNCT01555125
What this trial is testing

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

Who this might be right for
Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 177
Large-scale testing (Phase 3)Study completedNCT01519089
What this trial is testing

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Who this might be right for
Psoriasis
Pfizer 95
Large-scale testing (Phase 3)Study completedNCT03668613
What this trial is testing

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 84
Testing effectiveness (Phase 2)Study completedNCT01071252
What this trial is testing

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Who this might be right for
Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 125
Large-scale testing (Phase 3)Study completedNCT02394561
What this trial is testing

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)

Who this might be right for
Plaque Type Psorisis
Novartis Pharmaceuticals 434
Large-scale testing (Phase 3)Study completedNCT01636687
What this trial is testing

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

Who this might be right for
Plaque-type Psoriasis
Novartis Pharmaceuticals 182
Testing effectiveness (Phase 2)WithdrawnNCT02011269
What this trial is testing

TSO for Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Coronado Biosciences, Inc.
Large-scale testing (Phase 3)Study completedNCT01412944
What this trial is testing

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

Who this might be right for
Plaque-type Psoriasis
Novartis Pharmaceuticals 43
Testing effectiveness (Phase 2)Study completedNCT03384745
What this trial is testing

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Who this might be right for
Psoriasis
Bond Avillion 2 Development LP 313
Large-scale testing (Phase 3)Study completedNCT01309737
What this trial is testing

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
Pfizer 960
Large-scale testing (Phase 3)Study completedNCT02684370
What this trial is testing

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
AbbVie 560
Large-scale testing (Phase 3)Study completedNCT01365455
What this trial is testing

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

Who this might be right for
Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 738
Large-scale testing (Phase 3)Study completedNCT03504852
What this trial is testing

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Who this might be right for
Moderate to Severe Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 331
Testing effectiveness (Phase 2)Study completedNCT04207801
What this trial is testing

A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis

Who this might be right for
Chronic Plaque-type Psoriasis
Aurigene Discovery Technologies Limited 90
Testing effectiveness (Phase 2)Study completedNCT00941031
What this trial is testing

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Who this might be right for
Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 404
Large-scale testing (Phase 3)WithdrawnNCT01900782
What this trial is testing

Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.

Who this might be right for
Psoriasis
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT01640951
What this trial is testing

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Who this might be right for
Moderate to Severe Chronic Plaque-Type Psoriasis
Novartis Pharmaceuticals 675
Large-scale testing (Phase 3)Study completedNCT01544595
What this trial is testing

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Who this might be right for
Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 1,147
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation